When was F2g founded?

F2g was founded in 1998 and raised its 1st funding round 4 years after it was founded.

Where is F2g located?

F2g is headquartered in Manchester, United Kingdom.

Which legal entities is F2g associated with?

F2g is associated with F2g Ltd and 1 other.

How many employees does F2g have?

As of Mar 31, 2026, the latest employee count at F2g is 97.

Is F2g a funded company?

F2g is a funded company, having raised a total of $353M across 13 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Sep 10, 2002.

How much is F2g worth?

The latest valuation of F2g is £***** as of Jul 07, 2021.

When was the latest funding round of F2g?

F2g's latest funding was a $***** Series H round on Sep 12, 2024, with participation from 10 investors.

What is the annual revenue of F2g?

Annual revenue of F2g is £81.5M as on Dec 31, 2022.

Where does F2g rank among its competitors?

F2g ranks 2nd amongst 29 active competitors, of which 8 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was F2g, which secured $100M in Sep, 2024.

Who are the top competitors of F2g?

F2g's top competitors include Scynexis, Pulmocide and Biosergen. Among them, F2g secured the most recent funding round in September, 2024.

F2g - 2026 Company Profile, Team, Funding, Competitors & Financials

F2g is a series H company based in Manchester (United Kingdom), founded in 1998. It operates as a Developer of therapeutic treatments for rare and life threatening infections. F2g has raised $353M in funding from investors like Morningside, Advent Life Sciences and Novartis, with a current valuation of £*****. The company has 29 active competitors, including 8 funded and 4 that have exited. Its top competitors include companies like Scynexis, Pulmocide and Biosergen.

Company Details

Developer of therapeutic treatments for rare and life threatening infections. Research focuses on identifying and creating pharmaceutical compounds to address fungal pathogens. These medical products aim to provide treatment options for patients affected by serious fungal conditions.

Website: f2g.com
Email ID: *****@f2g.com
Phone Number: +1 **********

Key Metrics

Founded Year

1998

Location

Manchester, United Kingdom

Stage

Series H

Total Funding

$353M in 13 rounds

Latest Funding Round

Series H, Sep 12, 2024, $*****

Post Money Valuation

£***** as on Jul 07, 2021

Investors

Morningside & 22 more

Ranked

2^nd among 29 active competitors

Annual Revenue

£81.5M as on Dec 31, 2022

Employee Count

97 as on Mar 31, 2026

Similar Companies

Scynexis & 37 more

View F2g's full profile

F2g is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
F2G Inc. CIN: 10215489 , United States, Active	Dec 05, 2022	-	8 (As on Dec 31, 2021)	-
F2g Ltd CIN: 3578625 , Germany, Active	Jun 09, 1998	$101M (As on Dec 31, 2022)	53 (As on Dec 31, 2024)

F2g has raised a total funding of $353M over 13 rounds. Its first funding round was on Sep 10, 2002. Its latest funding round was a Series H round on Sep 12, 2024 for $*****. 10 investors participated in its latest round. F2g has 23 institutional investors.

Here is the list of recent funding rounds of F2g:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 12, 2024	9733835	Series H	6748051	9720918	2115069	1046083
Aug 04, 2022	7032946	Series E	6840241	1584191	7440239	Novo Holdings & 3 more
Aug 12, 2020	1364275	Series D	1293576	6803166	Cowen & 4 more	4299597

Access funding benchmarks and valuations. Sign up today!

View details of F2g's funding rounds and investors

Here are the details of F2g's key team members:

Francesco Maria Lavino: CEO of F2g.
Contact Info: 1 email address

F2g's Board of Directors

F2g's board has 12 active members. Patrick Volkert Jozef Johannes Vink, Francesco Maria Lavino and Kaasim Mahmood are part of team and Timothy Anderson, Henry Bradford Skinner, Nanna Liebach Luneborg, Naveed Siddiqi, William Henry Lewarne West, Sylvie Louise Gregoire, Camilla Soenderby, Tobias George Sykes and Joseph Anderson are independent board members.

Here is the list of F2g's board of directors:

Name	Type	Representing	Status	Duration
Patrick Volkert Jozef Johannes Vink	Team	-	Current	7y 1m
goutupp	Team	-	Current	7y 4m
ldpyqxu	Team	-	Current	6y 8m
ztgxpjt	Team	-	Past	9y 4m
agwebez	Team	-	Past	4y 3m
bwktcle	Team	-	Past	1y 3m
Timothy Anderson	Independent board member	-	Current	5y 8m
eggmmdc	Independent board member	-	Current	6y 1m
ydcslaw	Independent board member	-	Current	6y 3m
nkhlme{	Independent board member	-	Current	8y 7m
dm{qody	Independent board member	-	Current	6y 5m
aucxkit	Independent board member	-	Current	5y 8m
twhwdpi	Independent board member	-	Current	6y 5m
gaicprl	Independent board member	-	Current	1y 6m
ea{ekhz	Independent board member	-	Current	1y 8m

View details of F2g's Founder profiles and Board Members

F2g's employee count trend

F2g has 97 employees as of Mar 26. Here is F2g's employee count trend over the years:

Uncover F2g's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of F2g include Scynexis, Pulmocide and Biosergen. Here is the list of Top 10 competitors of F2g, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Scynexis 1999, Jersey City (United States), Public	Developing glucan synthase inhibitors for the treatment of fungal infections.	$62.7M	Societe Generale, KBL & 14 others	70/100
2nd	F2g 1998, Manchester (United Kingdom), Series H	Developer of therapeutic treatments for rare and life threatening infections	$353M	Cowen, Sectoral & 21 others	61/100
3rd	Pulmocide 2013, London (United Kingdom), Series C	Developer of inhaled antifungal medicines for treating respiratory lung infections	$205M	Pictet Group, Vivo Capital & 15 others	55/100
4th	Biosergen 2004, Solna (Sweden), Funding Raised	Developer of anti-fungal therapeutics for fungal infections	-	Rosetta Capital, BtoV	45/100
5th	Amplyx Pharmaceuticals 2006, San Diego (United States), Acqui-Hired	Pharmaceutical company focused on innovative medicines, vaccines, and expanded access programs	$144M	RiverVest Venture Partners, Sofinnova Investments ... & 16 others	43/100
6th	Viamet Pharmaceuticals 2005, Durham (United States), Acqui-Hired	Innovation hub revolutionizing healthcare, education, safety, energy, and technology with AI	$161M	Woodford Investment Management, Defense.gov ... & 7 others	41/100
7th	Elion Therapeutics 2024, New York City (United States), Series B	Developer of therapeutics for invasive fungal infections	$81M	Deerfield, AMR Action Fund & 1 others	39/100
8th	Morphobloc 2016, Umea (Sweden), Unfunded	Developer of antifungal agents to treat fungal diseases	-	-	33/100
9th	Nexmed 1995, San Diego (United States), Deadpooled	Drug developer for nail fungus and sexual disorders	$6.3M	-	33/100
10th	Mycovia Pharmaceuticals 2018, Durham (United States), Funding Raised	Developer of small molecule based therapeutics for the treatment of recurrent vulvovaginal candidiasis	-	NovaQuest Capital Management, HHS	33/100